Recent news highlights Nu Skin's Q3 2026 earnings call and financial performance, with earnings and revenues lagging estimates. Prior quarters showed mixed results with some revenue declines year-over-year. The company continues to provide detailed earnings call transcripts and operational updates.

• Nu Skin's Q3 2026 earnings and revenues lagged estimates, as discussed in the earnings call transcript [N1] and earnings report [N2].
• Q2 2026 earnings met estimates but revenues declined year-over-year, with highlights provided in earnings call and report [N5][N6][N7].
• The company maintains transparency through regular earnings calls and detailed public disclosures [N1][N5][N6].
• Industry peers such as e.l.f. Beauty and Hershey reported stronger earnings and revenue performance in recent quarters [N3][N4].
• Zacks.com featured Nu Skin among highlighted companies in July 2026, indicating ongoing market interest [N8].

Nu Skin benefits from a broad global sales force and a hybrid manufacturing model that combines third-party sourcing with in-house production in key markets like Mainland China and the U.S. This structure supports product quality control and supply chain management. The company's detailed financial disclosures and consistent earnings calls enhance transparency and investor understanding. Its liquidity position, with a current ratio above 2, indicates solid short-term financial health. The company's ability to manage selling expenses and maintain a motivated sales force is a key operational strength.

Recent quarterly results indicate challenges with revenue growth, as Q3 2026 earnings and revenues lagged estimates and Q2 2026 revenues declined year-over-year despite earnings meeting estimates. The company reported a slight net loss and negative EPS for the quarter ended September 30, 2026. The reliance on third-party suppliers outside Mainland China may expose the company to supply chain risks and cost fluctuations. Exchange rate risks affect gross margins due to revenue recognition in local currencies and purchasing in U.S. dollars. Selling expenses remain significant, which could pressure operating margins if sales growth slows.

Nu Skin's moat is supported by its established global direct sales network and manufacturing capabilities in Mainland China and the U.S., enabling control over product quality and supply chain. Its diversified sourcing strategy balances third-party suppliers with self-manufacturing, allowing flexibility and responsiveness to market demands. The company's brand recognition in the beauty and wellness sector and its incentive-driven sales force contribute to customer loyalty and market penetration. Additionally, its financial liquidity and operational scale provide resilience against market fluctuations and competitive pressures.

• Revenue and Earnings Volatility: Recent quarterly results show fluctuations with Q3 2026 earnings and revenues lagging estimates and Q2 2026 revenues declining year-over-year, indicating potential volatility in financial performance.
• Supply Chain and Manufacturing Risks: Dependence on third-party suppliers outside Mainland China and self-manufacturing in Mainland China and the U.S. exposes the company to supply chain disruptions, cost variability, and operational risks.
• Currency Exchange Risk: Gross margins are subject to exchange rate fluctuations because the company purchases goods in U.S. dollars but recognizes revenue in local currencies, impacting consolidated profitability.
• High Selling Expenses: Selling expenses, including commissions, incentives, and sales force labor costs, especially in Mainland China, represent the largest operating expense and could pressure margins if sales growth slows.
• Regulatory and Market Risks: The company operates in multiple international markets with varying regulatory environments and consumer preferences, which may affect product acceptance and compliance costs.

• Nu Skin Enterprises, Inc. operates in the beauty and wellness products sector with a global sales force.
• The company sources most of its beauty and wellness products from third-party suppliers and manufacturers globally, except in Mainland China where it operates manufacturing facilities producing the majority of products sold there and some exported products.
• Nu Skin also produces some products in the United States through its Rhyz Manufacturing entities.
• Revenue recognition is based on transferring products to customers, primarily recognized at shipping point, net of returns which historically are less than 5% of annual revenue.
• Cost of sales includes costs of purchased and self-manufactured products, inventory adjustments, manufacturing and distribution occupancy costs, labor costs, freight and import duties, and royalties for licensed technologies.
• Selling expenses are the most significant operating expense, including sales commissions, incentives, sales force conventions, and labor-related expenses for the sales force, especially in Mainland China.
• As of September 30, 2026, the company reported cash and cash equivalents of $164.9 million and short-term investments of $1.7 million, with current assets of $479.4 million and current liabilities of $235.2 million, resulting in a current ratio of 2.04 and a cash ratio of 0.71.
• The company reported a net loss of $742,000 and basic and diluted EPS of -$0.02 for the quarter ended September 30, 2026.
• Recent quarterly earnings calls and reports indicate that Nu Skin's Q3 2026 earnings and revenues lagged estimates, and Q2 2026 earnings met estimates but revenues declined year-over-year.
• The company has disclosed no material changes in risk factors from its 2025 Annual Report on Form 10-K.
• The company has a history of quarterly earnings calls and public disclosures providing transparency into its financial performance and operational updates.